Penumbra (PEN) Stock Forecast & Price Target

$287.80 -3.88 (-1.33%)

Closing price 02/24/2025 03:59 PM Eastern

Extended Trading

$287.70 -0.11 (-0.04%)

As of 08:04 AM Eastern

Penumbra - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
3

Buy
13

Based on 16 Wall Street analysts who have issued ratings for Penumbra in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 3 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for PEN.

Consensus Price Target

$292.64
1.68% Upside

According to the 16 analysts' twelve-month price targets for Penumbra, the average price target is $292.64. The highest price target for PEN is $340.00, while the lowest price target for PEN is $238.00. The average price target represents a forecasted upside of 1.68% from the current price of $287.81.

Get the Latest News and Ratings for PEN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Penumbra and its competitors.

PEN Analyst Ratings Over Time

Type	Current Forecast 2/26/24 to 2/25/25	1 Month Ago 1/27/24 to 1/26/25	3 Months Ago 11/28/23 to 11/27/24	1 Year Ago 2/26/23 to 2/26/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	11 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$292.64	$261.36	$230.92	$305.36
Forecasted Upside	1.68% Upside	-4.70% Downside	-5.42% Downside	32.03% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

PEN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PEN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Penumbra Stock vs. The Competition

Type	Penumbra	Medical Companies	S&P 500
Consensus Rating Score	2.88	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	1.68% Upside	27,528.15% Upside	14.30% Upside
News Sentiment Rating	Positive News See Recent PEN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/19/2025	JPMorgan Chase & Co. 2 of 5 stars	Robert Marcus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$230.00 ➝ $285.00	-7.38%
2/19/2025	Truist Financial 2 of 5 stars	David Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$285.00 ➝ $325.00	+5.84%
2/19/2025	Royal Bank of Canada 4 of 5 stars	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$285.00 ➝ $313.00	+4.17%
2/19/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jason Mills Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$323.00 ➝ $340.00	+13.64%
2/19/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Sachdeva Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$305.00 ➝ $320.00	+18.09%
2/19/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt O'Brien Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$250.00 ➝ $330.00	+21.78%
2/19/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$275.00 ➝ $305.00	+12.55%
2/19/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kallum Titchmarsh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$240.00 ➝ $260.00	-4.05%
2/19/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/19/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$305.00 ➝ $328.00	+21.04%
Get the Latest News and Ratings for PEN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.
12/17/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$275.00	+11.23%
12/11/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$220.00 ➝ $245.00	-4.74%
11/26/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$232.00 ➝ $270.00	+9.80%
9/17/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$238.00	+27.23%
9/3/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/3/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$263.00	+29.99%
6/26/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$325.00 ➝ $376.00	+13.18%
5/3/2023	58.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 08:05 AM ET.

PEN Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Penumbra is $292.64, with a high forecast of $340.00 and a low forecast of $238.00.
: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 3 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PEN shares.
: According to analysts, Penumbra's stock has a predicted upside of 1.68% based on their 12-month stock forecasts.
: Over the previous 90 days, Penumbra's stock had 1 upgrade by analysts.
: Penumbra has been rated by research analysts at Canaccord Genuity Group, Citigroup, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Penumbra more than other "medical" companies. The consensus rating score for Penumbra is 2.88 while the average consensus rating score for "medical" companies is 2.82. Learn more on how PEN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:PEN) was last updated on 2/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Penumbra (PEN) Stock Forecast & Price Target